Direct hospitalization costs of children with Mycoplasma pneumoniae pneumonia from 2013 to 2025 in China
A longitudinal retrospective single-center study
Bibliographic Data
| ID | 22068075 |
|---|---|
| Authors | Anle Shen (Shanghai Children's Medical Center), Zhiling Li (Shanghai Children's Medical Center), S Joseph Huang (0000-0003-4987-4756, Shanghai Children's Medical Center), Shiying Huang (0000-0002-0370-1553, Department of Clinical Pharmacy, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine), Tao Xu (0000-0002-0501-6445, Shanghai Children's Medical Center), Yejian Wang (0000-0002-8089-0706, Shanghai Children's Medical Center), Yong Yin (0000-0003-2321-9200, Shanghai Children's Medical Center, corresponding author), Jiande Chen (Shanghai Children's Medical Center, corresponding author) |
| Year | 2026 |
| Volume | 14 |
| Pages | 1762614-1762614 |
| Publication date | 2026-02-17 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2026.1762614 |
| PMID | 41783713 |
| OpenAlex | W7129343504 |
| Language | EN |
| References cited | 29 |
Background: pneumonia (MPP) is one of the most common type of community-acquired pneumonia. Due to the diversity in treatment measures and macrolide-resistant, the medical burden of hospitalized children remains uncertain. Methods: This study conducted a retrospective analysis of pediatric patients diagnosed with MPP and hospitalized at Shanghai Children's Medical Center over a 13-year period, from January 2013 to June 2025. The duration of hospital stay, total hospitalization costs, and drug costs per hospitalization were analyzed by year, corticosteroid administration, and presence of macrolide-resistant genes. Results: A total of 4,684 hospitalized children with MPP were included. The median age of the cohort was 6.50 years (quartile: 4.20-8.30 years), and the median duration of hospital stay was 5.00 days (quartile: 4.00-7.00 days). The median cost per hospitalization was $1,250.52 (quartile: $1,016.06-$1,612.27), while the median drug cost per hospitalization was $124.02 (quartile: $75.00-$199.31). Significant differences were observed in the duration of hospital stay, total costs, and drug costs per hospitalization between the age groups < 3, 3-6, 6-10, and ≥10 years. Additionally, significant differences were found between patients who received corticosteroids and those who did not, in terms of hospital stay duration, total costs, and drug costs per hospitalization. Conclusions: The medical burden associated with MPP in children under 3 years of age warrants attention and should be a focus of medical reimbursement policy considerations
Cohort · Medical costs · Medical record · Mycoplasma pneumoniae · Pneumonia · Reimbursement · Retrospective cohort study · Antibiotics Pharmacokinetics and Efficacy · Pneumonia and Respiratory Infections · Respiratory viral infections research
| Highly cited | No |
|---|